MedPath
HSA Approval

CLARIPEN GRANULES FOR ORAL SUSPENSION 250 mg/5 ml

SIN12033P

CLARIPEN GRANULES FOR ORAL SUSPENSION 250 mg/5 ml

CLARIPEN GRANULES FOR ORAL SUSPENSION 250 mg/5 ml

July 26, 2002

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

GRANULE, FOR SUSPENSION

ORAL

Medical Information

J01FA09

clarithromycin

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

ELPEN PHARMACEUTICAL CO INC

Sun Pharmaceutical Industries Limited (DP Intermediate)

Active Ingredients

CLARITHROMYCIN

250 mg/5 ml

Clarithromycin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CLARIPEN GRANULES FOR ORAL SUSPENSION 250 mg/5 ml - HSA Approval | MedPath